Long-term outcomes and prognostic factors of patients with lung metastases from differentiated thyroid cancer after radioiodine therapy in Japan
-
- Akatani Norihito
- Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa 920-8641, Japan
-
- Wakabayashi Hiroshi
- Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa 920-8641, Japan
-
- Kayano Daiki
- Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa 920-8641, Japan
-
- Inaki Anri
- Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa 920-8641, Japan
-
- Takata Aki
- Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa 920-8641, Japan
-
- Hiromasa Tomo
- Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa 920-8641, Japan
-
- Yamase Takafumi
- Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa 920-8641, Japan
-
- Kunita Yuji
- Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa 920-8641, Japan
-
- Watanabe Satoru
- Department of Functional Imaging and Artificial Intelligence, Kanazawa University, Kanazawa 920-8641, Japan
-
- Mori Hiroshi
- Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa 920-8641, Japan
-
- Saito Shintaro
- Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa 920-8641, Japan
-
- Nakajima Kenichi
- Department of Functional Imaging and Artificial Intelligence, Kanazawa University, Kanazawa 920-8641, Japan
-
- Kinuya Seigo
- Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa 920-8641, Japan
Search this article
Description
<p>Long-term survival in patients with differentiated thyroid cancer (DTC) and lung metastasis remains unexplored in Japan. This study aimed to investigate the long-term survival and prognostic factors of radioiodine therapy (RIT) in a University Hospital setting. This retrospective study included 62 patients with lung metastases from DTC who received RIT between March 2005 and December 2016. According to the 131I whole-body scan and chest computed tomography results, lung metastases were classified as 131I-avid or non-131I-avid, and miliary, micronodular, or macronodular metastases. The 5- and 10-year overall survival (OS) rates from the initial RIT were calculated by the Kaplan–Meier method, and a proportional hazard fit analysis was performed to determine prognostic factors. With a median follow-up of 7.9 years, the 5- and 10-year OS rates from the initial RIT were 93% and 72%, respectively. Univariable and multivariable analyses of patient subgroups revealed that macronodular lung metastases (defined as nodules >1 cm), older age at initial RIT, and high thyroglobulin values (>400 ng/mL) at initial RIT predicted low OS. The 5- and 10-year OS rates of DTC patients with lung metastases were similar to those in previous Japanese reports, which included a smaller sample size compared with ours. Patients with ≤1 cm lung metastases, aged ≤55 years, and a thyroglobulin level of ≤400 ng/mL at the initial RIT had favorable outcomes.</p>
Journal
-
- Endocrine Journal
-
Endocrine Journal 70 (3), 315-322, 2023
The Japan Endocrine Society